Navigation Links
US, Indian Doctors Bag Thai Medical Awards

Four doctors from the US and India received the Prince Mahidol Award 2006 from Thailand's King Bhumibol Aulyadej here for their contribution// to medical and public health services.

They received the award Wednesday for their achievements in the discovery, introduction and widespread use of oral re-hydration solution (ORS) or oral re-hydration therapy (ORT).

Stanley G. Schultz from the US University of Texas Medical School at Houston, American doctors David R. Nalin and Richard A. Cash, and Indian doctor Dilip Mahalanabis were presented the award in the field of medicine at the Chakri Throne Hall, the Grand Palace in Bangkok.

The Thai king praised the awardees as "excellent examples of those who truly perform good deeds for the sake of goodness, because such achievements are not meant for any individual but for the benefit of mankind as a whole".

The ORS, consisting of salt, sugar and water, was introduced in 1960s as a simple, low-cost and easily accessible solution to treat dehydration from cholera and diarrhoea.

Since early 1970s, with the widening use of the therapy throughout the world, especially among developing countries, ORS has benefited millions of lives around the world. It is estimated that each year 500 million packs of ORS are used in more than 60 developing countries.

The beauty of ORS is that it is not only cheap, but its ingredients are easy to avail and compose, the awardees agreed.

However, they added that to reduce costs and improve access to drugs and medical technologies, efforts are needed from scientists, private institutions and governments to commit themselves to creating a healthy world.

Sponsored by a Thai royal family foundation, the Prince Mahidol Award is conferred annually to individuals or institutions who make outstanding contributions to the advancement of medical and public health services for humanity all over the world.


'"/>




Page: 1 2

Related medicine news :

1. Indian Prime Minister has successful Knee Replacement Surgery
2. Development of AIDS vaccine -- Chiron Corp in talks with four Indian cos
3. Indian Doctor granted US patent on organ regeneration
4. Heart attack kills one in every 10 Indians
5. Indian Cherry: Richest Source of Vitiamin C
6. Indian Nationals with Foreign Medical Degrees can now practice in India
7. An Indian Bride with signs of SARS
8. Are Indians aware of SARS ?
9. Indians Stay Away from Coke, Pepsi After Toxin Scare
10. Indian pharma industry upbeat on WTO drug deal
11. Indian Treatment for Iraqi Babies
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Indian Doctors Bag Thai Medical Awards

(Date:5/16/2008)...ath the lining of the uterus (submucosal) are more...erine artery embolization (UAE) but usually dont c.... , The study included 49 patients with 140 fib...after UAE. The study found that 39 of these were s...al cavity after UAE, said Sachit Verma, MD, lead a...
(Date:5/16/2008)... May 19 at 10:15 a.m. Eastern Time, VANCOUVER, Ma...Corporation (TSX: RBM, OTCBB: RPBIF) today announc...scheduled to present at the Rodman & Renshaw,5th A...9th at 10:15 a.m.,EDT., A live web cast of the pr...site at, http://www.responsebio.com/newsroom_event...
(Date:5/16/2008)...d benefit most from chemo after surgery, study say... A panel of 15 genes may help determine which pati...ill experience a recurrence and, therefore, benefi..., By extension, the same genetic signature may ...of the cancer who would be able to forego chemothe...
(Date:5/16/2008)...udents learn the lesson of helping others ...NJING, China, May 16 /PRNewswire/ -- In the afterm...e youngest members of China are,looking for ways t...und the,country, schools are running donation driv... principal, Ms. Zhang Lijun, the 190-student stron...
Breaking Medicine News(10 mins):Health News:Response Biomedical Corporation to Present at Rodman & Renshaw 5th Annual Global Healthcare Conference 2Health News:Gene Signature May Predict Recurrence of Lung Cancer 2Health News:Gene Signature May Predict Recurrence of Lung Cancer 3Health News:Chinese Preschoolers Participate in Fund Drive to Help the Victims of Sichuan Quake 2
...dy and you are on a dieting course, there might be...searchers. Nutrition scientists from// Arizona Sta...in the body has a direct relation with the lower b...min C in the blood stream, it could cause increase...
...the risk of obesity, say scientists. Researcher Vi...ice in children’s diet and body mass index (BMI) o...nclusion. // According to foodconsumer.org, he f...cantly lower z-scores for body mass index for thei...
...s been found that children who have the habit of w...han if they don't watch. // And it has also been f... of watching TV during lunchtime, ate comparativel...ows. Dr. Lori Francis, assistant professor of biob...
... health emergencies like predicting about the deve...cientists have devised a simulator, which could ma...bird flu pandemic based on today's environment of ...m of scientists from Los Alamos National Laborator...
Other Medicine News:Health News:Vital Facts of Short Term Diets - Catch The Vitamin Behind An Ample Waist! 2Health News:Viewing TV During Lunch Affects Children's Food Intake 2Health News:Supercomputers To Assist In Thwarting Bird Flu Epidemic In Future 2Health News:Supercomputers To Assist In Thwarting Bird Flu Epidemic In Future 3Health News:Supercomputers To Assist In Thwarting Bird Flu Epidemic In Future 4
(Date:5/16/2008)...DGEWATER, N.J., May 16 /- Data from t... mean baseline hemoglobin (Hb) levels,and the rate...fect of,restrictions on reimbursement for erythrop...nts on the nation,s blood supply, will be presente...CO) Annual Meeting later this,month. The meeting w...
(Date:5/16/2008)...,s Technology Enables First-Ever PEGylation of a S...Therapeutic Activity, SAN CARLOS, Calif., May 16 ...daq: NKTR ) announced initial results today from .... The data shows significant,anti-tumor activity i...,also demonstrates that Nektar,s small molecule PE...
(Date:5/16/2008)...le Molecule with Dual Mechanism May Offer Novel Ap...Management, NEW ORLEANS, May 16 /PRNewswire-First... in the discovery and development of novel small,m...0, its first-in-class,Dual Acting Receptor Antagon... pressure reductions in a Phase 2a study in patien...
(Date:5/15/2008)...DCLIFF LAKE, N.J., May 15 /- Eisai Co...sults from 16 clinical data abstracts about,compou...rtfolio and,preclinical oncology research have bee...ting of the American Society of Clinical Oncology ...e 3, 2008., A wide variety of abstracts on Eisai ...
Breaking Medicine Technology:New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 2New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 3New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 4New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 5New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nation's Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting 6Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 2Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 3Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 4Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 5Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 2Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 3Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 4Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 5Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 6Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 7Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 8Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 2Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 3Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 4Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 5Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 6Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 7Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 8Angiotech to participate in Lehman Brothers Healthcare Conference 4021 1Nuvelo Announces Phase 2 SONOMA 3 Trial Did Not Meet Target Product Profile and Discontinues Alfimeprase Development 1542 1Nuvelo Announces Phase 2 SONOMA 3 Trial Did Not Meet Target Product Profile and Discontinues Alfimeprase Development 1542 2Nuvelo Announces Phase 2 SONOMA 3 Trial Did Not Meet Target Product Profile and Discontinues Alfimeprase Development 1542 3Nuvelo Announces Phase 2 SONOMA 3 Trial Did Not Meet Target Product Profile and Discontinues Alfimeprase Development 1542 4Clovis age overkill didnt take out Californias flightless sea duck 2530 1Clovis age overkill didnt take out Californias flightless sea duck 2530 2USP Announces Revised Glycerin Monograph 4019 1USP Announces Revised Glycerin Monograph 4019 2USP Announces Revised Glycerin Monograph 4019 3
The NOW® Malaria Test is a field or laboratory test for the differential diagnosis of a Malaria infection. It is intended for the detection of circulating Plasmodium falciparum (P.f.) antigen
...re Monitor (PCM) and Central Station provide an ex...nds the cardiac cath or electrophysiology lab to h...or EP procedures, providing both physiomonitoring ...either standalone or on its own network. Witts Cen...
For the critical care environment, telemetry, emergency room and other monitoring areas.
DS 7600 Central Station
Medicine Products: